Many therapies are available to help treat indolent B-cell NHL. Your doctor may treat you with one therapy or decide to combine more than one therapy. Therapies may include chemotherapy, biotherapy, and radiation treatment.
TREANDA® is a unique type of chemotherapy used to treat patients with indolent B-cell NHL that has progressed during or within 6 months of treatment with rituximab (a biotherapy) or a rituximab-containing regimen.
The goal of these treatments is to reduce or eliminate the presence of indolent B-cell NHL cells in your body, and TREANDA has been shown to help many patients.
Back to top
TREANDA is a chemotherapy with alkylating properties, which means it can kill indolent B-cell NHL cells that have progressed. It has a unique design that combines two kinds of chemical structures. TREANDA can kill cancer cells by several biologic pathways. The way TREANDA works has been studied in a laboratory, but how it specifically works is still being investigated.
Back to top
TREANDA for injection is indicated for the treatment of patients with indolent B-cell non-Hodgkin’s lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. TREANDA is also indicated for the treatment of patients with chronic lymphocytic leukemia (CLL). Efficacy relative to first-line therapies other than chlorambucil has not been established.
The following serious adverse reactions have been associated with TREANDA: myelosuppression, infections, infusion reactions and anaphylaxis, tumor lysis syndrome, skin reactions including SJS/TEN, other malignancies, and extravasation. Some of these reactions have been fatal, including myelosuppression, infections, and SJS/TEN (when TREANDA was administered concomitantly with allopurinol and other medications known to cause SJS/TEN). Patients should be monitored closely for these reactions and treated promptly if any occur. Adverse reactions may require interventions such as decreasing the dose of TREANDA, or withholding or delaying treatment. Myelosuppression is frequently severe and should be expected when treating patients with TREANDA.
TREANDA is contraindicated in patients with a known hypersensitivity to bendamustine or mannitol. Women should be advised to avoid becoming pregnant while using TREANDA.
The most common non-hematologic adverse reactions associated with TREANDA (frequency ≥15%) are nausea, fatigue, vomiting, diarrhea, pyrexia, constipation, anorexia, cough, headache, weight decreased, dyspnea, rash, and stomatitis. The most common hematologic abnormalities associated with TREANDA (frequency ≥15%) are lymphopenia, anemia, leukopenia, thrombocytopenia, and neutropenia.
Please see full Prescribing Information.